Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05672420 Not yet recruiting - Anemia Clinical Trials

Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Start date: January 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.

NCT ID: NCT05653960 Not yet recruiting - Colorectal Cancer Clinical Trials

Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

This study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.

NCT ID: NCT05653284 Not yet recruiting - Clinical trials for Advanced Malignant Tumors

A Study of AK130 in Patients With Advanced Malignant Tumors

Start date: January 2023
Phase: Phase 1
Study type: Interventional

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.

NCT ID: NCT05652855 Not yet recruiting - Clinical trials for Advanced or Metastatic Solid Tumors

Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

Start date: January 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB088C in participants with advanced or metastatic solid tumors.

NCT ID: NCT05650385 Not yet recruiting - Neoplasms Malignant Clinical Trials

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of two parts: a once-weekly (QW) dosing phase and a biweekly (Q2W) dosing phase, which will explore the possibility of Q2W dosing of B1962 based on the PK data obtained in the QW phase. The study will determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for B1962 as a single agent.

NCT ID: NCT05649618 Not yet recruiting - Solid Tumor Clinical Trials

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Start date: December 5, 2022
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TILs) therapy in patients with Advanced malignant solid tumors. TILs are expanded from tumor resections or biopsies, and after ex vivo stimulation, activation and extensive expansion, are reinfused to patients after non-myeloablative lymphocyte-depleting preparative regimen.

NCT ID: NCT05648994 Not yet recruiting - Solid Tumors Clinical Trials

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Start date: December 2022
Phase: Early Phase 1
Study type: Interventional

New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a Cancer-Testis Antigen (CTA) which is expressed in various tumors. After selected the high affinity TCR gene to NY-ESO-1, the researchers insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. Then the engineered cells are re-infused in the patients with tumors for curing the tumor patient or prolonging life.

NCT ID: NCT05647954 Not yet recruiting - Clinical trials for Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Start date: December 31, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver.

NCT ID: NCT05644509 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in patients with advanced malignant solid tumors. The purpose of this study is to evaluate the safety, tolerability, anti-tumor activity, immunogenicity, immune response, pharmacokinetic (PK) characteristics and shedding characteristics of Revottack injection combined with PD-1 inhibitor in patients with advanced solid tumors.

NCT ID: NCT05642949 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

Start date: January 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.